Skip to content

Polaryx Therapeutics, Inc. PLYX Deferred Tax Liabilities, Other

Deferred Tax Liabilities, Other at other companies

Arthur J. Gallagher logo
Arthur J. GallagherAJG
$4M+100%
BK
BKBK
$215M+13.8%
PNC Financial Services logo
PNC Financial ServicesPNC
$455M-3.6%
Williams Companies logo
Williams CompaniesWMB
$193M+32.2%
The Travelers Companies logo
The Travelers CompaniesTRV
$86M+22.9%
General Dynamics logo
General DynamicsGD
$315M0.0%

Other financials

Income statement

See full
Operating income-$2.0M+61.2%
Net income-$2.5M+49.6%
EPS (diluted)-$0.05+54.5%

Balance sheet

See full
Cash & equivalents$3.1M+1,132%
Total equity$2.5M-41.5%
Total assets$3.5M

Cash flow

See full
Operating cash flow-$2.1M-191%

Valuation

See full
Market cap$115.64M

Returns & leverage

See full
Return on equity-1,209.8%
Current ratio3.5×

Where this comes from

Reported directly by Polaryx Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:DeferredTaxLiabilitiesOther.

The official record: Polaryx Therapeutics, Inc. ’s 10-K, filed March 24, 2026, on SEC EDGAR. View the filing →

Ask your AI about Polaryx Therapeutics, Inc. 's deferred tax liabilities, other.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Polaryx Therapeutics, Inc. 's deferred tax liabilities, other?
Polaryx Therapeutics, Inc. (PLYX) reported deferred tax liabilities, other of $250K in Q4 2025.